(PR-inside.com) http://www.bms.com - Bristol-Myers Squibb Company (NYSE:BMY) today announced that Christopher Perley has been named vice president and general manager of its Devens biologics manufacturing facility. In this role, Perley will be responsible for continuing the supervision of the project to build the Devens facility and will have overall management responsibility for the site and facility when it becomes operational in 2011. 'With an approved capital expenditure of $750 million, the Devens facility represents the largest capital investment in the history of Bristol-Myers Squibb,' said Carlo de Notaristefani, president of Technical Operations, Bristol-Myers Squibb. 'As the Company evolves toward a ..
More...
More...